159 related articles for article (PubMed ID: 32857108)
1. Ulcerative Colitis in Adults.
Glick LR; Cifu AS; Feld L
JAMA; 2020 Sep; 324(12):1205-1206. PubMed ID: 32857108
[No Abstract] [Full Text] [Related]
2. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
4. Bugs and drugs: Predicting response to therapy.
Ananthakrishnan AN
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():27. PubMed ID: 30187562
[No Abstract] [Full Text] [Related]
5. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
6. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
9. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing].
Lasson A
Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2645-9. PubMed ID: 21137533
[No Abstract] [Full Text] [Related]
10. Diagnosis and Management of Crohn Disease.
Feld L; Glick LR; Cifu AS
JAMA; 2019 May; 321(18):1822-1823. PubMed ID: 30969326
[No Abstract] [Full Text] [Related]
11. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
13. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
[TBL] [Abstract][Full Text] [Related]
14. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
[No Abstract] [Full Text] [Related]
15. What is the faecal calprotectin test?
Drug Ther Bull; 2014 Sep; 52(9):102-4. PubMed ID: 25213590
[TBL] [Abstract][Full Text] [Related]
16. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
Papi C; Fascì-Spurio F; Rogai F; Settesoldi A; Margagnoni G; Annese V
Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
[TBL] [Abstract][Full Text] [Related]
17. [Role of biological markers in inflammatory bowel disease].
Gisbert JP; González-Lama Y; Maté J
Gastroenterol Hepatol; 2007 Mar; 30(3):117-29. PubMed ID: 17374324
[TBL] [Abstract][Full Text] [Related]
18. Integrating a treat to target approach into clinical practice in 2020.
Kennedy NA
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():6-7. PubMed ID: 33817849
[No Abstract] [Full Text] [Related]
19. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission".
Pasta A; Calabrese F; Bodini G
J Gastrointestin Liver Dis; 2024 Jun; 33(2):281. PubMed ID: 38944863
[No Abstract] [Full Text] [Related]
20. Active ulcerative colitis diagnosed by (18)F-FDG PET/CT in an anti-TNF alpha treated patient with no visible luminal lesions on colonoscopy.
Parbo P; Stribolt K; Rittig CS; Gormsen LC
Int J Colorectal Dis; 2014 May; 29(5):643-4. PubMed ID: 24531694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
